MillerKnoll (NASDAQ:MLKN – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday.
MillerKnoll Price Performance
Shares of NASDAQ:MLKN opened at $24.68 on Monday. The company has a 50-day moving average price of $28.30 and a two-hundred day moving average price of $27.36. The company has a quick ratio of 0.92, a current ratio of 1.53 and a debt-to-equity ratio of 0.93. MillerKnoll has a twelve month low of $19.10 and a twelve month high of $31.73. The firm has a market capitalization of $1.77 billion, a PE ratio of 22.23, a P/E/G ratio of 0.99 and a beta of 1.18.
MillerKnoll (NASDAQ:MLKN – Get Free Report) last released its quarterly earnings data on Thursday, September 19th. The company reported $0.36 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.04). MillerKnoll had a net margin of 2.27% and a return on equity of 10.94%. The firm had revenue of $861.50 million during the quarter, compared to the consensus estimate of $889.38 million. During the same quarter last year, the business posted $0.37 earnings per share. MillerKnoll’s revenue was down 6.1% compared to the same quarter last year. Equities analysts forecast that MillerKnoll will post 2.21 EPS for the current year.
Institutional Investors Weigh In On MillerKnoll
MillerKnoll Company Profile
MillerKnoll, Inc researches, designs, manufactures, and distributes interior furnishings worldwide. It operates through three segments: Americas Contract, International Contract & Specialty, and Global Retail. The company also provides seating products, furniture systems, other freestanding furniture elements, textiles, leather, felt, home furnishings and related services, casegoods, storage products, as well as residential, education, and healthcare furniture solutions.
See Also
- Five stocks we like better than MillerKnoll
- How to Find Undervalued Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Election Stocks: How Elections Affect the Stock Market
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Dividend Capture Strategy: What You Need to Know
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for MillerKnoll Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MillerKnoll and related companies with MarketBeat.com's FREE daily email newsletter.